



Published in final edited form as:

Cancer Res. 2022 April 01; 82(7): 1409–1422. doi:10.1158/0008-5472.CAN-21-2897.

A urinary drug-disposing approach as an alternative to intravesical chemotherapy for treating non-muscle invasive bladder cancer

Vanessa Bellat, PhD¹, Adam O. Michel, DVM, DACVP², Charlene Thomas, MS³, Tracy Stokol, BVSc, PhD⁴, Benjamin B. Choi, MD⁵, Benedict Law, PhD^{1,*}

¹Molecular Imaging Innovations Institute, Department of Radiology, Weill Cornell Medicine, 413 East 69th Street, New York, NY 10021, USA.

²Laboratory of Comparative Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

³Division of Biostatistics, Department of Population Health Sciences, Weill Cornell Medicine, 402 East 67th Street, New York, NY 10065, USA.

⁴Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Upper Tower Road, Ithaca, New York, NY 14853, USA.

⁵Department of Urology, Weill Cornell Medicine, 115 East 61st Street, New York, NY 10065, USA.

Abstract

The standard treatment of non-muscle invasive bladder cancer (NMIBC) is transurethral resection of the tumors, followed by intravesical therapy (IT), which comprises a direct instillation of a solution of Bacillus Calmette-Guérin vaccine or chemotherapy into the bladder. However, the recurrence rate in this disease remains unacceptably high. IT is a local treatment that fails to reach tumors developed in the upper urinary tract (ureter and renal pelvis). The catheterization procedure required for IT is invasive, painful, and poses an increased infection risk resulting in poor patient quality of life and compliance. There is an unmet need for a potent, comprehensive, and non-invasive option. Without chemical modifications, peptides are rapidly removed by renal clearance. This “shortcoming” can be advantageous when used as a drug carrier for directing therapy to NMIBC. Here we develop a urinary drug-disposing (UDD) approach to improve NMIBC treatment. A 12-amino acid bio-inert peptide (Bdd) that can be exclusively eliminated via renal filtration was generated for delivering the microtubule inhibitor DM1 to NMIBC with minimal non-specific accumulation in other organs. The UDD approach prolonged survival of mice bearing human bladder tumors. Unlike IT, the treatment was given non-invasively (intravenously). Furthermore, it was more effective at suppressing tumor growth

*Correspondence to: Benedict Law sbl2004@med.cornell.edu.

Authors' Contribution

V. Bellat: Conceptualization, data curation, formal analysis, investigation, methodology, validation, visualization, writing-original draft, writing-review & editing. **A. O. Michel:** Formal analysis, methodology, validation. **C. Thomas:** Formal analysis. **T. Stokol:** Formal analysis, methodology, validation. **B. Choi:** Conceptualization, funding acquisition, validation. **B. Law:** Conceptualization, funding acquisition, methodology, project administration, resources, supervision, writing-original draft, writing-review & editing.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

than clinically used IT (mitomycin) and safer than free DM1. The application of this urinary drug-disposing approach to treat kidney tumors and deliver other drugs such as doxorubicin was also demonstrated. Overall, the rapid renal clearance of peptides can be exploited to direct cancer therapies to the urinary system.

Keywords

Intravesical therapy; emtansine; urothelial cancer; urinary system; drug delivery

Introduction

Urothelial carcinoma, also known as bladder cancer (BC), is one of the most expensive life-time cancers to treat due to the high recurrence rate, repeated surgeries, and constant monitoring and treatment (1). More than 75–80% of BC are non-muscle invasive (NMIBC) (2). The standard treatment is transurethral surgical resection, followed by intravesical therapy (IT). IT is a direct instillation of solutions of Bacillus Calmette-Guérin (BCG) immunotherapy or chemotherapy into the bladder, via a catheter, to prevent disease recurrence (3,4). Because the treatment is local, IT possesses the advantage of minimizing systemic absorption and off-target toxicity (5). However, the recurrence rate of NMIBC remains unacceptably high (up to 80%) (6–8). The physiological need to urinate makes it difficult for patients, especially the elderly, to hold the instilled drug solution for longer than 1–2 hours. This limits the drug-tumor contacting time (9,10). Patient compliance is also poor, as the catheterization procedure is invasive (11). IT can cause pain, infection, significant urinary symptoms, or complications such as bladder perforation and perivesical fat necrosis (12), leading to discontinuation of treatment. Importantly, IT is unable to dispense drugs to tumors that may occur in more proximal portions of the upper urinary tract, such as the ureter and the renal pelvis. There is also a significant shortage of BCG due to a global increase in demand and limited supply (13–15). A critical result: surgeons are often compelled to remove the kidney and ureter, even in the case of less aggressive cancers. There is an unmet clinical need for a more effective drug delivery approach that is non-invasive, can access the entire urothelium, has a longer duration of drug-tumor exposure, and improves patient compliance by eliminating IT-associated morbidity. The goal of this study is to develop a urinary drug-disposing (UDD) approach to overcome the drug delivery barrier for NMIBC treatment.

Different approaches have been proposed to improve intravesical chemotherapy (ITC) treatment. To prolong treatment duration, a thermal-sensitive hydrogel, UGN-102, was designed to convert into a semi-solid drug depot inside the bladder and slowly release mitomycin (MIT). A gemcitabine (GEM)-containing semipermeable silicon tube, GemRis, which functions as an osmotic pump, has also been developed to control the release of GEM (16). Other treatments are currently being tested in clinical trials for patients who do not respond to BCG. Oportuzumab monatox is an antibody-protein conjugate that targets tumor cells expressing EpCAM (17). Adstiladrin is a nonreplicating adenovirus vector that encodes the human IFN α -2b gene (18). The resulting IFN α -2b proteins, synthesized and expressed in a large quantity, display an antitumor activity through inhibition of angiogenesis and

induction of apoptosis in human bladder cancer cells. However, all the aforementioned approaches are invasive, requiring catheterization and/or surgical procedures. Alternatively, renal-clearable nanoparticles can be used as drug carriers (19–22), but they are known to be non-specifically captured by the reticuloendothelial system, leading to a high off-target accumulation in the liver.

Advances in phage display have led to the discovery of many bioactive peptides that target the urinary system (URS) (23–25). For example, a galectin-3 targeting peptide, G3-C12, has been used for delivering captopril, an angiotensin-converting enzyme inhibitor (25). Another peptide, (KKEEE)₃K, has been used to carry ciprofloxacin (26–28). These peptides were pharmacologically active. They primarily targeted the kidneys by binding to cell-surface receptors, and prolonged the post-delivery local retention. They have not been applied to BC treatment. Further, without chemical modifications, a peptide is not a good drug candidate or carrier. It displays unfavorable pharmacokinetics (PK), is rapidly degraded by protease enzymes (29–31), and can be eliminated by renal filtration. In the present studies, we exploited a peptide's rapid renal clearance to our advantage for disposing treatments to the URS. Specifically, we generated a small, 12-amino acid, negatively charged peptide (Bdd) that can bypass the reticuloendothelial system and other organs, and is exclusively excreted into the urine with minimal reabsorption. We propose using it as an alternative to ITC for minimizing off-target accumulation in other organs, promoting drug delivery to the URS, and prolonging bladder retention time, resulting in a comprehensive and more effective BC treatment.

Materials and Methods

Chemicals and Supplies

2(1*H*-benzotriazole-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate (HBTU) and the *N*-hydroxybenzotriazole (HOBt) were purchased from Vivitide (Gardner, MA). All protected amino acids, rink amide MBHA resin, and *N*-methylmorpholine (NMM) were supplied by Gyros Protein Technologies (Tucson, AZ). Polyethylene glycol (PEG₃) was obtained from Creative PEGWorks (Durham, NC). Trifluoroacetic acid (TFA), piperidine, thioanisole, anisole, 1,2-ethanedithiole, methyl-*tert*-butyl ether, *N,N*-diisopropylethylamine (DIPEA), dimethylformamide (DMF), acetonitrile (ACN), *N*-methyl-2-pyrrolidone (NMP), sodium carbonate, Sephadex G25, L-glutathione reduced (GSH), lipopolysaccharide (LPS), and *cis*-dichlorodiammine platinum (II) (cisplatin) were purchased from Sigma Aldrich (Saint-Louis, MO). Succinimidyl 3-(2-pyridyldithio)propionate (SPDP) was supplied by Invitrogen (Carlsbad, CA). *p*-SNC-deferoxamine (DFO) was from Macrocyclics Inc. (Plato, TX). *N*2'-deacetyl-*N*2'-(3-mercapto-1-oxopropyl)-maytansine (DM1) and aldorubicin HCl (aldox) were from MedKoo Biosciences (Morrisville, NC). Doxorubicin (DOX) and gemcitabine (GEM) were obtained from LC Laboratories (Woburn, MA). Mitomycin (MIT) was supplied by Selleckchem (Houston, TX). Cyanine5.5 NHS ester was purchased from Lumiprobe Corporation (Hallandale Beach, FL) and luciferin was from Caliper LifeScience (Hopkinton, MA).

Peptide synthesis

All peptides were synthesized on a solid-phase peptide synthesizer (PS3, Gyros Protein Technologies, Tucson, AZ) using the *N*- α -Fmoc methodology on Rink amide resin, as previously described (32–35). The side-chain protected amino acids (0.4 mmol) were attached to the resin (385 mg, 0.1 mmol) by stepwise elongation using NMM as a base, HBTU/HOBt as coupling reagents, and piperidine (20% in DMF v/v) as a deprotecting agent. A β -alanine was incorporated at the peptide N-terminal as a spacer for further conjugation of the desired moieties, including fluorophore (Cyanine5.5), chelator (DFO), or linker (SPDP) prior to peptide cleavage.

Immunogenicity assay

Female BALB/cJ mice (Cat# 000651, Jackson Laboratory, Bar Harbor, ME) were treated with a single dose of Bdd or LPS (5 mg/kg) via tail-vein injection (n=3/group). Mice administered with PBS were used as negative controls. Blood samples were collected 4 h later via retro-orbital sinus puncture technique, and the concentration of the innate immune and inflammatory cytokines IL-1 β , IL-2, IL-6, IL-10, TNF- α , and INF- γ in plasma was measured with commercial sandwich enzyme-linked immunosorbent assay kits. ELISA assays were performed according to the manufacturer's instructions (Invitrogen, Carlsbad, CA).

Methods to incorporate different functionalities to peptide

Cyanine5.5 NHS ester (50mg, 1.4 eq) in DMF (4 mL), DFO (25 mg, 1 eq) in DMSO (4 mL), or SPDP (25 mg, 1 eq) in NMP (4 mL), were added to the resin (0.05 mmol, 1 eq) and allowed to react overnight at room temperature. For fluorophore and chelator conjugation, the reactions were performed in the presence of an organic base (DIPEA, 1 mL). The peptides were then removed from the resin using a cleaving cocktail (5 mL) containing TFA/thioanisole/1,2-ethanedithiol/anisole (90:5:3:2) for 4 h and precipitated in methyl-*tert*-butyl ether. The resulting peptides (Cy-peptide, DFO-peptide, and SPDP-peptide) were purified to >98% purity using reverse-phase high performance liquid chromatography (rp-HPLC, Agilent, Santa Clara, CA) and were characterized by MALDI-TOF analysis (Tufts Medical School, Boston, MA) to confirm their molecular weights.

Synthesis of cleavable drug-peptide conjugates

DM1 (1 mg, 1 eq) was added to SPDP-peptide (10 mg, 3 eq) in a cosolvent of NMP (100 μ L) and phosphate-buffered saline (PBS; 10 mM, pH 7, 100 μ L), and allowed to react for 2 days at room temperature. The DM1-peptide was then purified by rp-HPLC. To conjugate aldox, a thiol-reactive side (cysteine) was introduced at the peptide N-terminal. Aldox (2 mg, 1 eq) was added to the peptide (10 mg, 3 eq) in PBS (10 mM, pH 7.4), and allowed to react for 30 minutes. The drug-peptide obtained was pH-sensitive and thereby was purified by rp-HPLC in neutral conditions (mobile phase A: PBS, mobile phase B: 90% ACN in PBS). Size exclusion chromatography (TipTop C-18 column) was used to remove the salt content. All the final drug-peptide conjugates were characterized using MALDI-TOF analysis and were quantified with UV absorbance, according to the

pre-determined extinction coefficient of DM1 ($\epsilon = 3,700 \text{ cm}^{-1} \text{ M}^{-1}$) or aldox ($\epsilon = 13,000 \text{ cm}^{-1} \text{ M}^{-1}$) in 5% (v/v) PBS in methanol.

Radiochemistry

^{89}Zr zirconium (^{89}Zr) was supplied by 3DImaging LLC (Little Rock, AR). The ^{89}Zr -oxalate (500 μCi) was first neutralized with an equivalent volume of sodium carbonate solution (2 M), and then added to the DFO-peptides (0.2 mg, 250 μL). After incubation for 1.5 h at room temperature, the radiolabeled peptides (^{89}Zr -peptides) were purified by size exclusion chromatography using Sephadex G-25 gel to remove the free zirconium.

Pharmacokinetic study

BALB/cJ mice (Cat# 000651, Jackson Laboratory, Bar Harbor, ME) were administered with ^{89}Zr -peptide or free ^{89}Zr (20 μCi , 100 μL) via tail-vein injections (n=4/condition). Blood samples (20 μL) were collected at various time intervals, using the retro-orbital sinus puncture technique. The radioactivities were measured on Wallac Wizard 2 gamma counter (Perkin-Elmer, Waltham, MA). The pharmacokinetic models and parameters of ^{89}Zr -peptides and free ^{89}Zr , including the serum half-life and the plasma clearance, were estimated by fitting the data for compartmental model selection using PKSolver 2.0 software.

$\mu\text{PET/CT}$ imaging and biodistribution study

BALB/cJ mice (Cat# 000651, Jackson Laboratory, Bar Harbor, ME) were intravenously injected with different ^{89}Zr -peptide analogues (20 μCi , 100 μL). $\mu\text{PET/CT}$ imaging was performed in animals with and without urine collection prior to the first imaging (n=4/analogue/condition). Whole-body images were acquired 1, 4, and 24 h after injection, using an Inveon $\mu\text{PET/CT}$ scanner (Siemens Medical Solutions, Malvern, PA). $\mu\text{PET/CT}$ maximum energy projections were processed using Amide v1.0.4 and Inveon Research Workplace software. The radioactivities at different regions of interest (ROI) were determined. For end-point biodistribution studies, the mice were euthanized 0.17, 1, 2, 5, and 7 days after treatment with ^{89}Zr -peptides (n=3/peptide analogue/time point). The radioactivities of the harvested organs were measured using the Wallac Wizard 2 gamma counter. The results were corrected from radioactive decay, and were expressed as a percentage of the injected dose (%ID) or percentage of injected dose per gram of tissue (%ID/g).

Fluorescence imaging

Female SHO mice (Cat# 474, Charles River Laboratories, Wilmington, MA) were administered with free Cyanine5.5 or Cy-peptide analogues (0.5 nmol of Cyanine5.5 content measured by UV absorbance at 680 nm) in a PBS solution (150 μL) via tail-vein injections (n=4/group). Real-time fluorescence imaging was performed using an In Vivo Xtreme imaging system (Bruker, Billerica, MA). Whole body fluorescence images were acquired 1 and 4 h post injection using the appropriate excitation (670 nm) and emission (750 nm) filters. The animals were then euthanized. The organs were excised to perform ex vivo fluorescence imaging. Imaging was also performed on urine samples (20 μL) collected from

separate animals 1, 4, and 6 h after i.v. injection of free dye or Cy-peptide analogues (n=4/treatment). Bruker MI software was used to process the fluorescence/bright light images and measure the fluorescence intensity in different ROIs. All the data were corrected to eliminate the organ or fluid auto-fluorescence.

Cell lines

MB49 murine bladder carcinoma cell line (Cat# SCC148) was supplied by EMD Millipore Corporation (Temecula, CA). UMUC-3 and T24 human urinary bladder cancer cell lines (Cat# CRL-1749 and Cat# HTB-4), and Renca murine kidney adenocarcinoma cell line (Cat# CRL-2947), were obtained from ATCC (Manassas, VA). Each cell line was cultured and maintained (no more than 10 passages after initial thawing) according to the company's instructions. Mycoplasma tests (Lonza, Basel, Switzerland) were performed periodically to ensure that there was no contamination. Both UMUC-3 and Renca cell lines were further transduced with GlowCell 16 FLuc-F2A-GFP lentivirus (Biosettia, San Diego, CA) carrying both firefly luciferase and green fluorescent protein (GFP) genes. Briefly, the cells were seeded in 6-well plates (0.25×10^6 cells/well) and incubated for 3 days with the virus (2×10^7 IU/well) in the presence of polybrene (10 $\mu\text{g}/\text{mL}$). To ensure more than 95% of cell purity, the cell lines were analyzed and sorted for GFP expression using flow cytometry. The successful transduction was further confirmed by imaging, using an EVOS FL Auto Fluorescence microscope (Life Technology, Carlsbad, CA).

Cell viability and cytotoxicity assay

Cancer cells (3×10^3 /well) were seeded on a flat bottom 96-well plate overnight. Different concentrations of DM1, gemcitabine (GEM), mitomycin (MIT), cisplatin (CIS), doxorubicin (DOX), aldorubicin (aldox), or drug-loaded peptides (DM1-peptide and aldox-peptide), were then added to the cells for 72 h and then washed twice with PBS (400 μL). CellTiter Glo reagent (Promega, Madison, WI) was added to each well (50 μL). The luminescence generated was recorded using a microplate reader (Tecan US Inc., Morrisville, NC). The dose response curves were plotted, and the half maximal inhibitory concentrations (IC_{50} values) were calculated using Graph Pad Prism 6.0 software.

In vitro drug release study

DM1-peptide conjugates (10 μM of drug content) were incubated in the presence of the reducing agent GSH (1 mM) in PBS buffer (800 μL). At different time intervals (0, 2, 4, 6, 8, 12, 24, and 48 h), a small amount of solution (100 μL) was taken out for rp-HPLC analysis using a C18 analytical column. The amount of DM1 active metabolites released over time was measured (absorbance detected at 254 nm) and then quantified. The experiment was performed independently in triplicate. A similar experiment was performed to quantify the release of aldox. Aldox-peptide conjugates (100 μM of drug content) were incubated in PBS buffer (800 μL) of different pH levels (7.4 and 5.5) in glass vials coated with silica to avoid non-specific adsorption on the reaction vessel surfaces (36,37). The amount of drug released over time was then measured as described above (absorbance detected at 480 nm). For accurate quantification, all the results were normalized compared to a DOX control incubated in similar conditions.

Animal care

All animals used for this project were housed in a pathogen-free barrier room, maintained at a controlled temperature (72 ± 2 °F) with daily 12 h cycles of light and dark. All the procedures conducted on mice were approved by the Weill Cornell Medical Center Institutional Animal Care and Use Committee (protocol # 2019–0003), and were consistent with the recommendations of the American Veterinary Medical Association and the National Institutes of Health Guide for the Care and Use of Laboratory Animals. The mice were allowed to acclimate for at least 7 days before performing any experiment. Immunocompromised NSG mice are susceptible to infection. Thus, the animals were fed a diet containing sulfatrim antibiotic (Envigo, Indianapolis, IN). Animals used for fluorescence imaging were fed with AING93 non-fluorescence diet (Envigo, Indianapolis, IN).

Therapeutic efficacy of drug-Bdd conjugates for treating BC

Animals were orthotopically implanted with tumors as previously described (38,39). Briefly, the urine of 7- to 9-week-old female NSG mice (Cat# 005557, Jackson Laboratory, Bar Harbor, ME) was removed through a sterile 26 G pediatric venous catheter (Covidien, Dublin, Ireland). A trypsin solution (0.125%, 80 μ L) was then delivered into the bladder. Subsequently, UMUC-3/GFP-Luc cells (4×10^4 cells) in culture media (50 μ L) were transferred into the bladders and allowed for seeding. Tumor progression was monitored by bioluminescence imaging using an In Vivo Xtreme imaging system (Bruker, Billerica, MA). Luciferin (3 mg) in PBS (100 μ L) was given to the animals (via intraperitoneal injection) 15 min prior to performing imaging. Once tumor progression was confirmed in bladders (based on bioluminescence signal), the animals were randomly assigned for weekly treatment with PBS, DM1, or DM1-Bdd (0.75 mg/kg of drug content) in saline (150 μ L) via tail-vein injection for 3 weeks (n=14/group). Separate groups of animals were assigned for intravesical DM1, DM1-Bdd (0.75 mg/kg of drug content), or MIT (1 mg/mL) in saline (50 μ L) treatments (n=14/group). The therapeutic efficacy was evaluated based on tumor growth inhibition (bioluminescence imaging) and long-term survival. Additional mice were recruited for histopathological analysis (n=3/group). These animals were immediately euthanized 1 week after the completion of the treatment schedule. The bladders were harvested and preserved in neutral buffered formalin (10%). The same experimental conditions were used for comparing the treatment outcomes among animals treated with PBS, aldox, or aldox-Bdd via tail-vein injection or intravesical administration (5mg/kg of drug content).

Evaluation of DM1-Bdd for kidney cancer treatment

Renca/GFP-Luc cells (4×10^3 cells) in PBS (3 μ L) were orthotopically implanted into the kidney capsules of 7- to 9-week-old female BALB/cJ mice (Cat# 000651, Jackson Laboratory, Bar Harbor, ME) as previously described (40). Tumor progression was confirmed by bioluminescence imaging using an In Vivo Xtreme imaging system (Bruker, Billerica, MA). The animals were randomly assigned into 4 groups for weekly treatment with PBS, DM1, or DM1-Bdd (0.75 mg/kg of drug content, 150 μ L) through tail-vein injection, or DM1-Bdd (0.75 mg/kg of drug content, 50 μ L) through intravesical

administration (n=14/treatment). The animals were monitored for tumor growth inhibition and survival as described above. Additional mice were used for histopathological analysis (n=4/group).

Histologic analysis

The tissue samples were fixed in 10% neutral buffered formalin, dehydrated with ethanol, and embedded in paraffin. The tissue sections (5 μ m) were stained with hematoxylin and eosin Y (H&E). For immunohistochemistry, the bladder sections were deparaffined and then rehydrated before incubation with anti-Ki67 or anti-GFP antibodies (Abcam, Cambridge, UK) overnight. Slides were then counterstained with hematoxylin. High resolution images were acquired using Aperio 9 Digital Pathology slide scanner (Leica Biosystems, Weltzar, Germany).

Necropsy

Seven- to 9-week-old female BALB/cJ mice (Cat# 000651, Jackson Laboratory, Bar Harbor, ME) were treated weekly with PBS, DM1, DM1-peptide (0.75 mg/kg of drug content, 150 μ L), or cisplatin (10 mg/kg, 150 μ L) via tail-vein injection (n=4/group). At the end of a 3-week treatment, mice were euthanized. The organs/tissues were harvested, fixed in 10% neutral buffered formalin for 2 days. Bones were decalcified in a formic acid solution (Surgipath Decalcifier I; Leica Biosystems, Weltzar, Germany). The samples were then embedded in paraffin, sectioned (5 μ m), and stained with H&E for examination by an ACVP board certified anatomic pathologist.

Nephrotoxicity studies

PBS, DM1, DM1-peptide, MIT, GEM, CIS (0.75 mg/kg of drug content, 150 μ L), or a high dose of CIS (10 mg/kg, 150 μ L), was administered to BALB/cJ mice (Cat# 000651, Jackson Laboratory, Bar Harbor, ME) via the tail veins (n=3/group). The level of acute renal injury biomarkers, neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) in the urine samples, was measured using ELISA assays according to the manufacturer's instructions (R&D Systems, Minneapolis, MN). The complementary histopathological analyses were performed on the kidneys of animals treated with PBS, DM1, DM1-Bdd, (0.75 mg/kg of drug content), or a high dose of CIS (10 mg/kg). All the animals (n=3/group) were euthanized at the end of the treatment and the kidneys were collected and fixed in 10% neutral buffered formalin. The tissues were then processed, embedded in paraffin, sectioned, and stained with H&E. Immunohistochemistry (IHC) for kidney injury (NGAL and KIM-1) was also performed.

Hematology and biochemistry

Blood samples were collected via cardiac puncture. A complete blood count, including red blood cell, white blood cell, reticulocyte, and platelet, with an automated differential leukocyte count, was performed using an IDEXX Procyte DX hematology analyzer (IDEXX, Westbrook, ME). Blood smears were prepared, stained with modified Wright's stain, examined in a blinded fashion by a board-certified veterinary clinical pathologist (T. Stokol), and imaged using a Nikon Eclipse TE2000-U fluorescent microscope equipped with

a photometrics CoolSNAP HQ² camera (Nikon Corporation, Tokyo, Japan). The blood was also centrifuged (1,500xG) for 15 min to obtain the serum for biochemical analysis using a Beckman Coulter AU680 analyzer (Beckman Coulter, Brea, CA).

Statistical analysis

Statistical analyses were performed using Graph Pad Prism 6.0 software and R v4.0.5 (R Foundation for Statistical Computing, Vienna, Austria) software. All data were presented as mean \pm standard deviation and significances were assigned at * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$. Significant differences between groups were determined using a 2-tailed Student's t-test. For survival evaluation, the Mantel-Cox Log-Rank test was performed to compare the survival curves of animals treated with i.v. DM1-Bdd or aldox-Bdd to other treatments. P-values were adjusted for multiple comparisons using the Benjamini & Hochberg method. All p-values were two-sided with statistical significance evaluated at the 0.05 alpha level. Ninety-five percent (exact) confidence intervals for all parameters were calculated to assess the precision of the obtained estimates.

Results

Bdd can be exclusively eliminated via renal clearance

Bdd was designed in *D*-configuration to avoid degradation by protease enzymes in the blood circulation (41). It was composed of multiple *D*-aspartic acid (d) and β -alanine (B) residues (Fig. 1A). The aspartic acids contributed to the overall negative charge, preventing non-specific uptake by major organs, and promoting renal clearance of the peptide (42,43). The B residues served as linkers to avoid the formation of a secondary structure. To investigate how the charges were critical for governing Bdd's in vivo behavior, we also synthesized a panel of Bdd analogues that were in *L*-configuration (BDD), neutral (BKD), carrying positive charges (BKK), and in pegylated form (PEG₃DD) for comparative studies. The peptides were labeled with ⁸⁹Zr, a long-lived radioisotope ($t_{1/2} = 78$ h), which allowed us to study the pharmacokinetics (PK) and long-term biodistribution (BD) using micro positron emission and computerized tomography (μ PET/CT) imaging. The radiolabeled peptides (⁸⁹Zr-peptides) were synthesized by first conjugating a deferoxamine (DFO) chelator to the peptide in solid phase after amino acid elongation. We then complexed ⁸⁹Zr with the resulting DFO-peptide conjugates in solution under basic conditions (Fig. 1B).

To compare the in vivo biodistribution of the ⁸⁹Zr-peptides, we injected them into BALB/cJ mice and acquired the whole-body μ PET/CT images. Our results showed that ⁸⁹Zr-Bdd and ⁸⁹Zr-BDD displayed minimal off-target delivery (Fig. 1C). We could not detect any radioactivity (peptide) in the major organs, except the kidneys. Both peptides were rapidly excreted into the urine within 1 hour after i.v. administration, as confirmed by the absence of radioactivity in the bladders, which were catheterized and emptied prior to imaging. Our results also showed that as much as 80% of the total injected dose (ID) appeared in the first urine sample collected from the animals injected with ⁸⁹Zr-Bdd (Fig. 1D), suggesting that the peptide was filtered via the glomerulus with minimal reabsorption. On the other hand, the positively charged ⁸⁹Zr-BKK was delivered to the liver in addition to the URS (Fig. 1C). We also compared renal uptake among the peptide analogues. Except for an initial

increase in PEG₃DD, they all showed reduced accumulation in kidneys over time (Fig. 1E). To determine the PK profile, we fit our experimental data into a two-compartment model. Our results showed that all the peptide analogues displayed shorter half-lives compared to the free ⁸⁹Zr (Fig. 1F). ⁸⁹Zr-Bdd had a terminal half-life of 0.53 hour and rapid plasma clearance (Supplementary Fig. 1A). We further performed an end-point biodistribution study of ⁸⁹Zr-Bdd. The results were in good agreement with the imaging and PK studies. As expected, we did not detect any peptide in major organs or blood circulation 4 hours after i.v. injection (Fig. 1G & Supplementary Fig. 1B). Despite the rapid clearance, 15.1% of ⁸⁹Zr-Bdd's ID was found in kidneys, which decreased to 2.1% after 7 days.

As a carrier of hydrophobic molecules

Most chemotherapeutics are hydrophobic molecules that display unfavorable PK and BD, leading to off-target delivery and undesired toxicity. We foresaw that the Bdd's rapid renal clearance could be beneficial for promoting drug delivery to the URS. To demonstrate that, we covalently attached a hydrophobic Cyanine5.5 fluorophore (Cy) as a drug model to the peptide analogues (Fig. 2A). We then injected the resulting conjugates (Cy-peptides) into hairless SHO mice for comparative delivery studies using optical imaging. Both Cy-Bdd and Cy-BDD could be rapidly eliminated via renal clearance. They reached the animals' bladders 1 hour after i.v. injections (Fig. 2B), with as much as 70–75% ID present in the urine (Fig. 2C). On the other hand, Cy-BKD, Cy-BKK, Cy-PEG₃DD, and free Cy were mainly taken up by liver and/or other organs, and slowly excreted from the body through renal clearance. We also performed ex vivo imaging of the harvested organs (Fig. 2D). As expected, the accumulation of Cy-Bdd or Cy-BDD in kidneys was minimal (Fig. 2E). Cy-PEG₃DD showed a prolonged retention in kidneys (Figs. 2D and E), which might explain the delayed renal excretion profile compared to the other peptide conjugates (Fig. 2C). The results were also in good agreement when using PEG₃DD to deliver ⁸⁹Zr (Fig. 1E). Overall, Bdd could be used for delivering hydrophobic molecules, such as Cy, to the URS while maintaining the comprehensive UDD properties. Unlike ⁸⁹Zr-Bdd, trace amounts of Cy-Bdd and Cy-BDD were taken up by the stomach, liver, and intestines. The biodistribution differences were likely attributed to the replacement of a negatively charged ⁸⁹Zr-DFO by the hydrophobic Cy. Fortunately, the Cy-Bdd's off-target accumulation was quickly eliminated by hepatic clearance within 24 hours (data not shown). However, further studies are needed to fine-tune the physicochemical properties (such as the surface charges) of Bdd and improve the urinary disposing efficiency.

As carrier of chemotherapeutics

The Bdd's excellent UDD properties prompted us to further investigate it for delivering chemotherapeutics for NMIBC treatment. Many peptides are immunogenic (44,45). We first confirmed that the Bdd peptide did not trigger innate immune responses. There was no increase of inflammatory cytokine levels (IL-1 β , IL-2, IL-6, IL-10, TNF- α , and INF- γ) in the plasma of BALB/cJ mice 4 hours after i.v. injection (Fig. 3A). Using the fluorescence Cy-Bdd, we further confirmed that the peptide could be taken up by human BC (UMUC-3) and murine kidney cancer (Renca) cells (Fig. 3B). We observed overlapping of the peptide (red) and lysosome (green) fluorescence, suggesting that cellular uptake of the peptide mainly occurred via endocytosis. As proof of principle, we selected emtansine

(DM1), a potent microtubule inhibitor, as a drug candidate. Compared to other conventional chemotherapeutics, DM1 was more potent than cisplatin (CIS), doxorubicin (DOX) and mitomycin (MIT), and as effective as gemcitabine (GEM) against UMUC-3, with IC_{50} values at the nanomolar (nM) range (Fig. 3C). The drug was also effective against the Renca cell line. Next, we synthesized a DM1-Bdd conjugate by attaching DM1 to Bdd via a cleavable disulfide linker (Fig. 3D), enabling drug release in a reducing environment, such as in the presence of intracellular glutathione (GSH) (Fig. 3E) (46,47). We also established the chemistry for conjugating other chemotherapeutics, such as aldoxorubicin (aldox), to Bdd (Fig. 3F). Aldox is a DOX derivative modified with a hydrazone linker, which is known to be sensitive to the acidic lysosome and tumor microenvironment. The drug release from the aldox-Bdd conjugate was pH-dependent (Fig. 3G). In terms of cytotoxicity, both DM1-Bdd and aldox-Bdd exhibited a similar potency to the corresponding free drugs against different murine (MB49) and human (UMUC-3 and T24) BC cell lines, as well as murine (Renca) kidney cancer cell line (Figs. 3H–I).

A more effective alternative to conventional ITC

Unlike with intravesical (i.t.) administration, animals did not need to void shortly after i.v. injection (Fig. 4A). DM1-Bdd, administered through i.v. injection, should prolong the drug's bladder-dwelling time. This, together with the unique UDD properties, should offer a more effective (compared to ITC) and safer (compared to systemic chemotherapy) therapeutic option when using Bdd as a drug carrier. However, Bdd could temporarily accumulate in kidneys (Figs. 1C and G). Therefore, prior to evaluating the therapeutic efficacy of DM1-Bdd, we first assessed the tolerability of the kidneys to a single injectable dose in healthy BALB/cJ mice. Our results showed that DM1-Bdd slightly increased levels of urinary tubular injury markers, kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL), in the urine 1 day after the injection (Fig. 4B). However, the increases were minimal and transient, returning to basal levels within 3 days. Histologic examination at 3 days after drug administration did not reveal any abnormalities in the kidneys, with no elevation of the immunoreactivity of the tissue sections for KIM-1 and NGAL, when compared to PBS (Fig. 4C). In contrast, other i.v. chemotherapeutics, including DM1, MIT, CIS, and GEM, showed a continued induction of KIM-1 and/or NGAL at this time point. We also found dilation and degeneration of tubular epithelium in animals treated with a high dose of i.v. CIS (positive control) (Fig. 4C).

We then evaluated DM1-Bdd for treating NSG mice bearing orthotopic human UMUC-3 tumors. Prior to implanting UMUC-3 cells into the animals' bladders, we stably transduced them with a dual luciferase and GFP reporter (Fig. 4D). This allowed us to monitor the disease progression with bioluminescence imaging (39). We also confirmed that the established tumors, growing in the lamina propria, were non-invasive in nature and limited to the urinary bladder submucosa (Fig. 4E). Compared to the clinically used ITC (i.t. MIT), both i.v. DM1 and DM1-Bdd were more effective in inhibiting tumor growth (Figs. 4F–G and Supplementary Figs. 2A–E) and prolonged animal survival (Fig. 4H). An i.v. injection of DM1-Bdd provided a better treatment outcome when compared to i.t. administration. According to the imaging data acquired during the 3 once-per-week treatments course, the antitumor activity of i.v. DM1-Bdd and DM1 was similar (Fig. 4F). However, those animals

treated with i.v. DM1-Bdd showed a significant improvement in overall survival (36% versus 0% survived after 100 days). In a separate experiment, we confirmed the therapeutic effect on tumor reduction by histology. Tumors of the animals treated with i.v. DM1-Bdd were smaller (Fig. 4I). Immunohistochemistry revealed fewer GFP-positive cells and lower proportion of neoplastic cells expressing the proliferation marker (Ki67), confirming the inhibition of tumor cell growth and proliferation (Fig. 4J and Supplementary Fig. 2F). More importantly, DM1-Bdd treatment was curative for 21% of the animals. The survivor mice lacked gross and histologic evidence (using GFP and Ki67 immunostaining) of tumors, suggesting they were disease-free after 210 days (Supplementary Fig. 2G). Bdd is a versatile delivery platform that can carry different chemotherapeutics. Aldox-Bdd was also able to prolong the animal survival compared to PBS and free DOX (Supplementary Figs. 3A–C). However, it was not as effective as DM1-Bdd in improving overall survival (Supplementary Fig. 3C). Surprisingly, mice treated with free DOX had a shorter life expectancy compared to the PBS control, with the animals continuously losing weight during DOX treatment (Supplementary Figs. 3D and E). They eventually died prior to receiving the final dose, suggesting drug-induced toxicity and mortality.

Anatomic flexibility

Next, we evaluated DM1-Bdd for treating renal carcinoma. We used a syngeneic mouse model for the studies, which involved a surgical implantation of Renca cells (stably transduced with GFP and Luc) into the capsule of the right kidney of BALB/cJ mice (Fig. 5A). The tumor growth was aggressive. A tumor mass of a substantial size developed as early as 1 week after implantation (Fig. 5B). Our imaging studies showed that i.v. DM1-Bdd was not only able to inhibit tumor progression (Figs. 5C and D) but also reduce tumor size, as shown by decreased bioluminescence signals in most of the animals during the treatment (Fig. 5E). There was 50% of survival after 160 days (Figs. 5F and G). On the other hand, all animals treated with either i.v. or i.t. DM1 died. In a separate experiment, we performed histological examination of the animals' kidneys one week after completing the treatment course (Fig. 5H). Minimal tumor was present in animals treated with i.v. DM1-Bdd, whereas tumors of animals treated with DM1 or PBS control were large and accompanied with an infiltration of mononuclear cells. Overall, our UDD approach was anatomically flexible and could be used for treating tumors located at the upper urinary tract.

Toxicity profile

Finally, we assessed the toxicity profile of DM1-Bdd in healthy BALB/cJ mice after completing 3 weeks of weekly treatments. DM1-Bdd did not affect the red blood cell, leukocyte, or platelet counts or morphologic features (Figs. 6A–B and Supplementary Fig. 4). On the other hand, DM1 induced reticulocytosis without apparent anemia, and an inflammatory response characterized by increased proportions of neutrophils, monocytes, and platelets. The positive control CIS was also toxic, as evidenced by thrombocytopenia and lymphopenia. We also performed serum biochemical analysis to assess for liver injury and renal function. DM1-Bdd was not hepatotoxic, with no significant alteration in the release of ALP, ALT, and AST enzymes (Fig. 6C and Supplementary Fig. 5). Importantly, the urea nitrogen/creatinine ratio was normal, suggesting that DM1-Bdd did not affect renal clearance of nitrogenous waste. Histopathologic studies further confirmed that there

was no morphological evidence of injury in the liver, spleen, heart, lungs, or kidneys of the animals treated with DM1-Bdd (Fig. 6D and Supplementary Fig. 6). In contrast, the biochemical testing showed that both DM1 and CIS induced hepatic and renal toxicity, as shown by increases in ALT and AST activities and BUN/CREA ratios (Fig. 6C). They also induced muscle injury (CK activity), which would partly explain the increases in the AST activity. Histologic examination also revealed that CIS caused degeneration and necrosis of the proximal renal tubules, lung inflammation, and depletion of both erythrocytes and extramedullary hematopoiesis (EMH) in spleen (Fig. 6D and Supplementary Fig. 6). Animals treated with DM1 showed similar renal damage but to a lesser degree. We also observed increased splenic and hepatic EMH with DM1, which may explain the observed reticulocytosis in the treated animals.

Discussion

Chemotherapeutics gain some selectivity by targeting tumor cells that proliferate rapidly (48). However, most of them are still toxic to both healthy and cancer cells. They are given by infusion so that they can be continuously administered at a higher total dose over a longer period of time. The goal is to achieve more effective treatment to improve patient tolerance to off-target toxicities by maintaining the drug's plasma concentration at a certain level and prolonging the tumor exposure to the drug. In the present study, we aimed to promote, rather than reduce, a drug's clearance as a non-invasive alternative of ITC. Many bioactive peptides have been approved for treating various diseases, including cancer, diabetes, and cardiovascular disease (49). Without chemical modifications, peptides have a short circulating half-life of several minutes. They are rapidly degraded by protease enzymes (29–31) and eliminated by renal filtration (50). We recognized that a peptide's rapid renal clearance could be advantageous as a drug carrier to dispose most systemically administered drugs in urine for treating NMIBC and reducing the unwanted systemic side-effects. We introduced a UDD approach using a bio-inert, negatively charged peptide (Bdd) that was uptaken minimally by the reticuloendothelial system and other organs, and was exclusively excreted into the urine. We employed Bdd for delivering DM1, a microtubule inhibitor. We selected DM1 as it was 100-fold more potent than commonly used BC drugs, including MIT, DOX, and CIS, against a panel of BC cell lines. Further, conjugating the drug to the Bdd peptide did not compromise cytotoxicity.

In terms of therapeutic efficacy, i.v. administered DM1-peptide conjugate (DM1-Bdd) improved overall survival in mice with BC compared to conventional i.t. MIT (Fig. 4H). It was also more effective compared to the same treatment given by i.t. (Figs. 4F–I). The improved efficacy was expected given that animals did not need to void shortly after i.v. injection (Fig. 4A). Promoting renal clearance could reduce a drug's off-target toxicity. DM1-Bdd did not induce unwanted toxicity (Fig. 6). In contrast, animals treated with DM1 or CIS showed evidence of hepatic and renal injury. We also highlighted the flexibility of the UDD approach in reducing drug-induced toxicity by using aldox-Bdd for BC treatment. Unlike free DOX, which caused mortality, we observed improved survival in animals treated with aldox-Bdd (Supplementary Fig. 3). However, compared to DM1-Bdd, the aldox-Bdd treatment only slowed down the cancer progression and did not eliminate

tumors in individual animals. The result was expected since DM1 is more potent than DOX (Fig. 3C).

ITC is a local treatment that only covers tumors in the bladder as the drug solution cannot reach the upper urinary tract. DM1-Bdd is administered through i.v. injection. This, together with the rapid renal clearance, should allow drugs to flush the entire URS. We applied DM1-Bdd to renal carcinomas and found that DM1-Bdd offered a significant survival benefit compared to the free drug. In fact, approximately 50% of the animals lacked gross or histologic evidence of the tumor one week after completing the treatment course. Intravenous drug administration will thus allow more comprehensive coverage of the URS when used for treating BC, as tumors can extend, migrate into, or recur throughout the entire urothelium, including the renal pelvis and the ureter from which 8–12% of the urothelial carcinomas originate (51). Currently, when treating patients with renal pelvic or ureteral tumors, surgeons are often left with no choice but to remove the entire kidney and ureter (even when the tumors are non-invasive) to prevent disease recurrence for URS tumors. We foresee that DM1-Bdd can potentially be a kidney-sparing treatment option for patients with upper tract urothelial cancers.

A drawback of IT is its poor patient compliance rate (16–30%) (11). Patients receiving ITC need to be catheterized weekly by trained personnel in hospital/clinic. Our i.v. DM1-Bdd treatment is minimally invasive, so can avoid complications associated with catheterization procedures and improve patient's quality of life and compliance. The lifetime management of BC is costly (52), and requires repeated treatments due to a high recurrence rate. Systemic administration of a chemotherapeutic, such as DM1-Bdd, will likely reduce BC treatment costs.

Overall, we developed a UDD approach that could minimize non-specific accumulation in other organs, and offer a comprehensive treatment by supplying drug to the entire URS, as a more effective alternative to ITC. The developed DM1-Bdd is clinically translatable. The United States Food and Drug Administration (FDA) has approved many peptides for treating different cancers. The employed DM1 is an active pharmacophore already used in antibody-drug conjugates, such as Herceptin-DM1 (T-DM1), for breast cancer treatment. Furthermore, the same approach of drug to peptide conjugation can be applied to treating other diseases, such as kidney and bladder infections, simply by replacing cytotoxic drugs with antibiotics.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Research reported in this publication was supported in part by the National Cancer Institute (CA222802 to B. Law) and the Radiology Department, WCM. We would like to acknowledge the Laboratory of Comparative Pathology Core Facility (MSKCC), partially funded by NCI grant P30 CA008748, for the preparation of the organ sections for histological and fluorescence analyses, as well as the Department of Pathology and Laboratory Medicine (WCM) for their help with the slice scanning of the histopathological samples. We would like also to thank Elizabeth Sweeney and Arindam RoyChoudhury for assisting with the statistical analyses of the survival studies. We would

like to express our gratitude to those anonymous patients for their financial support of the studies. Finally, the authors thank Cynthia Fox for the editing of this manuscript.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

- Williams SB, Howard LE, Foster ML, Klaassen Z, Sieluk J, De Hoedt AM, et al. Estimated Costs and Long-term Outcomes of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Guerin in the Veterans Affairs Health System. *JAMA Netw Open* 2021;4:e213800 [PubMed: 33787908]
- Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder Cancer: A Review. *JAMA* 2020;324:1980–91 [PubMed: 33201207]
- Sylvester RJ, Oosterlinck W, Holmang S, Sydes MR, Birtle A, Gudjonsson S, et al. Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? *Eur Urol* 2016;69:231–44 [PubMed: 26091833]
- Huncharek M, Geschwind JF, Witherspoon B, McGarry R, Adcock D. Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. *J Clin Epidemiol* 2000;53:676–80 [PubMed: 10941943]
- Griffin JG, Holzbeierlein J. Side effects of perioperative intravesical treatment and treatment strategies for these side effects. *Urol Clin North Am* 2013;40:197–210 [PubMed: 23540778]
- Addeo R, Caraglia M, Bellini S, Abbruzzese A, Vincenzi B, Montella L, et al. Randomized phase III trial on gemcitabine versus mitomycin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. *J Clin Oncol* 2010;28:543–8 [PubMed: 19841330]
- Messing EM, Tangen CM, Lerner SP, Sahasrabudhe DM, Koppie TM, Wood DP Jr., et al. Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. *JAMA* 2018;319:1880–8 [PubMed: 29801011]
- Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guerin. *Eur Urol* 2016;69:60–9 [PubMed: 26210894]
- Schmittgen TD, Wientjes MG, Badalament RA, Au JL. Pharmacodynamics of mitomycin C in cultured human bladder tumors. *Cancer Res* 1991;51:3849–56 [PubMed: 1906778]
- De Bruijn EA, Sleetboom HP, van Helsdingen PJ, van Oosterom AT, Tjaden UR, Maes RA. Pharmacodynamics and pharmacokinetics of intravesical mitomycin C upon different dwelling times. *Int J Cancer* 1992;51:359–64 [PubMed: 1592527]
- Tapiero S, Helfand A, Kedar D, Yossepowitch O, Nadu A, Baniel J, et al. Patient Compliance With Maintenance Intravesical Therapy for Nonmuscle Invasive Bladder Cancer. *Urology* 2018;118:107–13 [PubMed: 29792974]
- Filson CP, Montgomery JS, Dailey SM, Crossley HS, Lentz H, Tallman CT, et al. Complications associated with single-dose, perioperative mitomycin-C for patients undergoing bladder tumor resection. *Urol Oncol* 2014;32:40 e1–8
- Tully KH, Cole AP, Krimphove MJ, Friedlander DF, Mossanen M, Herzog P, et al. Contemporary treatment patterns for Non-Muscle Invasive Bladder Cancer: Has the Use of Radical Cystectomy changed in the BCG Shortage Era? *Urology* 2020;20:30983–3
- Desouky E. BCG versus COVID-19: impact on urology. *World J Urol* 2020;1–5 [PubMed: 31788716]

15. Packiam VT, Wertz RP, Steinberg GD. Current Clinical Trials in Non-muscle-Invasive Bladder Cancer: Heightened Need in an Era of Chronic BCG Shortage. *Curr Urol Rep* 2019;20:84 [PubMed: 31781942]
16. Grimberg DC, Shah A, Inman BA. Overview of Taris GemRIS, a Novel Drug Delivery System for Bladder Cancer. *Eur Urol Focus* 2020;6:620–2 [PubMed: 31561993]
17. Kowalski M, Guindon J, Brazas L, Moore C, Entwistle J, Cizeau J, et al. A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guerin. *J Urol* 2012;188:1712–8 [PubMed: 22998907]
18. Shore ND, Boorjian SA, Canter DJ, Ogan K, Karsh LI, Downs TM, et al. Intravesical rAd-IFNalpha/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. *J Clin Oncol* 2017;35:3410–6 [PubMed: 28834453]
19. Du BJ, Jiang XY, Das A, Zhou QH, Yu MX, Jin RC, et al. Glomerular barrier behaves as an atomically precise bandpass filter in a sub-nanometre regime. *Nature Nanotechnology* 2017;12:1096–+
20. Ni D, Jiang D, Im HJ, Valdovinos HF, Yu B, Goel S, et al. Radiolabeled polyoxometalate clusters: Kidney dysfunction evaluation and tumor diagnosis by positron emission tomography imaging. *Biomaterials* 2018;171:144–52 [PubMed: 29689411]
21. Burns AA, Vider J, Ow H, Herz E, Penate-Medina O, Baumgart M, et al. Fluorescent silica nanoparticles with efficient urinary excretion for nanomedicine. *Nano Lett* 2009;9:442–8 [PubMed: 19099455]
22. Liu J, Yu M, Zhou C, Yang S, Ning X, Zheng J. Passive tumor targeting of renal-clearable luminescent gold nanoparticles: long tumor retention and fast normal tissue clearance. *J Am Chem Soc* 2013;135:4978–81 [PubMed: 23506476]
23. Audige A, Frick C, Frey FJ, Mazzucchelli L, Odermatt A. Selection of peptide ligands binding to the basolateral cell surface of proximal convoluted tubules. *Kidney Int* 2002;61:342–8 [PubMed: 11786117]
24. Odermatt A, Audige A, Frick C, Vogt B, Frey BM, Frey FJ, et al. Identification of receptor ligands by screening phage-display peptide libraries ex vivo on microdissected kidney tubules. *J Am Soc Nephrol* 2001;12:308–16 [PubMed: 11158220]
25. Geng Q, Sun X, Gong T, Zhang ZR. Peptide-drug conjugate linked via a disulfide bond for kidney targeted drug delivery. *Bioconjug Chem* 2012;23:1200–10 [PubMed: 22663297]
26. Wischnjow A, Sarko D, Janzer M, Kaufman C, Beijer B, Brings S, et al. Renal Targeting: Peptide-Based Drug Delivery to Proximal Tubule Cells. *Bioconjug Chem* 2016;27:1050–7 [PubMed: 26999755]
27. Christensen EI, Birn H. Megalin and cubilin: multifunctional endocytic receptors. *Nat Rev Mol Cell Biol* 2002;3:256–66 [PubMed: 11994745]
28. Lenhard SC, McAlexander A, Virtue A, Fieles W, Skedzielewski T, Rambo M, et al. In Vivo Imaging of Small Molecular Weight Peptides for Targeted Renal Drug Delivery: A Study in Normal and Polycystic Kidney Diseased Mice. *J Pharmacol Exp Ther* 2019;370:786–95 [PubMed: 30936291]
29. Bottger R, Hoffmann R, Knappe D. Differential stability of therapeutic peptides with different proteolytic cleavage sites in blood, plasma and serum. *PLoS One* 2017;12:e0178943 [PubMed: 28575099]
30. Barrett TM, Chen XS, Liu C, Giannakoulis S, Phan HAT, Wang J, et al. Studies of Thioamide Effects on Serine Protease Activity Enable Two-Site Stabilization of Cancer Imaging Peptides. *ACS Chem Biol* 2020;15:774–9 [PubMed: 32141733]
31. Aneja R, Grigoletto A, Nangarlia A, Rashad AA, Wrenn S, Jacobson JM, et al. Pharmacokinetic stability of macrocyclic peptide triazole HIV-1 inactivators alone and in liposomes. *J Pept Sci* 2019;25:e3155 [PubMed: 30809901]
32. Bellat V, Lee HH, Vahdat L, Law B. Smart Nanotransformers with Unique Enzyme-Inducible Structural Changes and Drug Release Properties. *Biomacromolecules* 2016;17:2040–9 [PubMed: 27180972]

33. Bellat V, Ting R, Southard TL, Vandat L, Molina H, Fernandez J, et al. Functional Peptide Nanofibers with Unique Tumor Targeting and Enzyme-Induced Local Retention Properties. *Adv Funct Mater* 2018;28
34. Law B, Weissleder R, Tung CH. Peptide-based biomaterials for protease-enhanced drug delivery. *Biomacromolecules* 2006;7:1261–5 [PubMed: 16602747]
35. Law B, Weissleder R, Tung CH. Protease-sensitive fluorescent nanofibers. *Bioconjug Chem* 2007;18:1701–4 [PubMed: 17915958]
36. Benvenuto JA, Anderson RW, Kerkof K, Smith RG, Loo TL. Stability and compatibility of antitumor agents in glass and plastic containers. *Am J Hosp Pharm* 1981;38:1914–8 [PubMed: 7325172]
37. Curry D, Scheller H, Lu M, Mkandawire M, Servos MR, Cui S, et al. Prevention of doxorubicin sorptive losses in drug delivery studies using polyethylene glycol. *RSC Advances* 2015; 5:25693–8
38. Huebner D, Rieger C, Bergmann R, Ullrich M, Meister S, Toma M, et al. An orthotopic xenograft model for high-risk non-muscle invasive bladder cancer in mice: influence of mouse strain, tumor cell count, dwell time and bladder pretreatment. *BMC cancer* 2017;17:790 [PubMed: 29169339]
39. Kasman L, Voelkel-Johnson C. An orthotopic bladder cancer model for gene delivery studies. *J Vis Exp* 2013:50181 [PubMed: 24326612]
40. Murphy KA, James BR, Wilber A, Griffith TS. A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies. *J Vis Exp* 2017
41. Feng Z, Xu B. Inspiration from the mirror: D-amino acid containing peptides in biomedical approaches. *Biomol Concepts* 2016;7:179–87 [PubMed: 27159920]
42. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. *Nat Biotechnol* 2015;33:941–51 [PubMed: 26348965]
43. Huang Y, Jiang K, Zhang X, Chung EJ. The effect of size, charge, and peptide ligand length on kidney targeting by small, organic nanoparticles. *Bioeng Transl Med* 2020;5:e10173 [PubMed: 33005739]
44. Flower DR. Designing immunogenic peptides. *Nat Chem Biol* 2013;9:749–53 [PubMed: 24231606]
45. Van Regenmortel MH. Antigenicity and immunogenicity of synthetic peptides. *Biologicals* 2001;29:209–13 [PubMed: 11851317]
46. Wagh A, Law B. Methods for conjugating antibodies to nanocarriers. *Methods Mol Biol* 2013;1045:249–66 [PubMed: 23913152]
47. Pillow TH, Sadowsky JD, Zhang D, Yu SF, Del Rosario G, Xu K, et al. Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates. *Chem Sci* 2017;8:366–70 [PubMed: 28451181]
48. Mitchison TJ. The proliferation rate paradox in antimetabolic chemotherapy. *Mol Biol Cell* 2012;23:1–6 [PubMed: 22210845]
49. Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. THPdb: Database of FDA-approved peptide and protein therapeutics. *PLoS One* 2017;12:e0181748 [PubMed: 28759605]
50. Wu H, Huang J. Optimization of Protein and Peptide Drugs Based on the Mechanisms of Kidney Clearance. *Protein Pept Lett* 2018;25:514–21 [PubMed: 29848260]
51. Transitional cell cancer of the renal pelvis and ureter treatment (PDQ(R)): Health Professional Version. PDQ Cancer Information Summaries. Bethesda (MD) 2002.
52. Kaye DR, Min HS, Herrel LA, Dupree JM, Ellimoottil C, Miller DC. Costs of Cancer Care Across the Disease Continuum. *Oncologist* 2018;23:798–8 [PubMed: 29567821]

Significance:

A non-invasive drug delivery approach that targets the urinary system overcomes the current barriers facing effective treatment of bladder cancer.




Fig. 1: Bdd shows remarkable urinary disposing properties.

A, A table showing the components and the net charges of BDD as well as its *D*-configuration (Bdd), neutrally charged (BKD), positively charged (BKK), and pegylated (PEG₃DD) counterparts. **B**, A synthetic scheme showing radiolabeling of the peptides with ⁸⁹Zr for comparative PK and biodistribution studies. **C**, Representative μPET/CT images of BALB/cJ mice acquired 1, 4, and 24 h after administration of different ⁸⁹Zr-radiolabeled peptides (20 μCi, 20 μg, in 100 μL PBS) via tail-vein injections (n=4/group). The whole-body images were acquired with or without emptying the animal’s bladders. **D**, Bar chart showing the amount of radioactivity in urine samples (20 μL) collected from animals (n=5) at different time intervals after administration of ⁸⁹Zr-Bdd. **E**, Comparing the renal clearance of the radiolabeled peptides. Plots showing the percentage of injected dose (%ID) in kidneys of the animals over time. The percentage of ID was calculated according to the radioactivity measured at the region of interest (ROI) of the acquired PET images. **F**, Comparing the

pharmacokinetic (PK) profiles of the radiolabeled peptides (n=4/analogue). Blood samples (20 μ L) were collected at various time intervals after injection of the peptides or free ^{89}Zr to the animals. The results (radioactivity measured in blood samples) were fit into a two-compartmental model for determining the $t_{1/2\alpha}$ (half-life of distribution phase) and $t_{1/2\beta}$ (half-life of elimination phase). The other PK parameters are available in Supplementary Fig. 1A. **G**, End-point biodistribution study of ^{89}Zr -Bdd. The animals were euthanized at different time intervals (n=4/time point) after administration of the peptide (20 μ Ci, 20 μ g, in 100 μ L PBS). The amount of peptide (radioactivity) in the harvested organs was determined. The results (corrected from decay) were expressed as %ID. (Student's t-test; **p<0.01, and ***p<0.001).




Fig. 2: Bdd effectively distributes the conjugated Cyanine5.5 fluorophore to the urinary system.

A, A synthetic scheme of the Cyanine5.5-labeled peptide (Cy-peptide) analogues. **B**, Representative merged fluorescence/white light-images of SHO mice acquired 1 and 4 h after tail-vein injection of the different Cy-peptide analogues (0.5 nmol, 150 μ L) or free Cyanine5.5 (n=4/group). **C**, Plots comparing the amount of fluorophore in urine (% of injected dose) based on the measured fluorescence. (Lower panel) Fluorescence image of the urine samples (20 μ L) collected from the same animals 1, 4, and 6 h after the Cy-peptides or fluorophore administration (n=4/group). For each time point, the bladders of the animals were completely emptied using a sterile 24 G pediatric venous catheter. **D**, Representative ex vivo merged fluorescence/bright light images of the organs harvested from animals 4 h after tail-vein injection of different Cy-peptides (n=4/group). **E**, Bar chart comparing peptide distribution in the harvested organs (n=4/group), based on the total fluorescence intensity. (Student's t-test; *p<0.05, **p<0.01, and ***p<0.001).




Fig. 3: Bdd as a carrier of chemotherapeutics.

A, Bdd does not trigger any innate immune response. No increase in the inflammatory cytokines concentrations was detected in the plasma of female BALB/cJ mice ($n=3/\text{group}$) 4 h after i.v. administration of the Bdd peptide (5 mg/kg, 150 μL). LPS was used as a positive control and concentrations of each cytokine were measured by ELISA kit. **B**, Cellular uptake of Cyanine5.5-labeled Bdd (Cy-Bdd). Representative fluorescence microscopic images of human UMUC-3 BC cells and murine Renca renal adenocarcinoma cells incubated for 6 and 24 h with Cy-Bdd (0.5 nmol). Dapi (9 μM) and LysoTracker-GFP (1 μM) were used for nuclear (blue) and organelle (green) staining, respectively, and were added to the cells 30 min prior to imaging. Scale bar is 25 μm . **C**, Comparing the potency of different chemotherapeutics (DM1, GEM, MIT, CIS, and DOX). UMUC-3 and Renca cells were incubated with the drugs at various concentrations for 72 h prior to measuring the cell viability. The dose response curves were plotted and the half maximal inhibitory concentrations (IC₅₀ values) of each drug calculated using Graph Pad Prism 6.0 software. **D**, Conjugation of DM1 to Bdd. The cleavable linker SPDP was first conjugated to the

peptide N-terminal in solid phase. DM1 was then added to the cleaved peptide in a solution mixture of PBS and NMP. **E**, Plot showing the percentage of accumulated DM1 released from the DM1-Bdd over time in PBS in the absence and presence of GSH (1 mM). The amount of drug released was quantified using rp-HPLC analysis (absorbance detected at 254 nm). **F**, Conjugation of aldox to Bdd. The peptide, supplemented with a N-terminal cysteine, was incubated with aldox in PBS (pH = 7.4) for 30 min prior to purification by rp-HPLC in neutral conditions. **G**, Plots showing the percentage of the accumulated DOX active metabolite released from aldox-Bdd (100 μ M) over time in PBS buffers with different pH values. The amount of drug released was quantified using rp-HPLC analysis (absorbance detected at 480 nm). **H**, DM1-Bdd displays a similar cytotoxicity compared to free drug against murine bladder (MB49), human bladder (UMUC-3 and T24), and murine kidney (Renca) cancer cell lines. Plots of relative cell viability against the drug concentration. **I**, Aldox-Bdd is more potent than free aldox. Plots of the relative cell viability against the drug concentration.




Fig. 4: Therapeutic efficacy of DM1-Bdd in treating bladder cancer.

A, Bar chart comparing the time when BALB/cJ mice ($n=20$ /group) needed to void naturally following i.v. or i.t. administration of PBS (80 μ L). The bladders were emptied prior to starting the experiment. Each animal was isolated for monitoring the urination pattern. **B**, Comparing the nephrotoxicity of DM1-Bdd to other chemotherapeutics. Bar chart showing the concentrations of renal injury biomarkers, NGAL and KIM-1, in urine collected from animals 1, 3, and 7 days after treatment with PBS, DM1 (0.75 mg/kg), DM1-Bdd (0.75 mg/kg of drug content), MIT (0.75 mg/kg), CIS (0.75 mg/kg), CIS (10 mg/kg), or GEM (0.75 mg/kg) via tail vein injection (150 μ L). (Student's t-test; * $p<0.05$, ** $p<0.01$, and *** $p<0.001$). **C**, Immunochemical staining for NGAL and KIM-1 was also performed. Representative microscopic images of kidney sections from BALB/cJ mice i.v. administered with PBS (150 μ L), DM1 (0.75 mg/kg, 150 μ L), DM1-Bdd (0.75 mg/kg of drug content, 150 μ L), or CIS (10 mg/kg, 150 μ L) as a positive control. The organs were harvested 3 days after the drug treatments and stained with H&E. Black arrows indicate the multifocal degeneration of the tubular epithelium after treatment with CIS. Red and green arrows

indicate renal tubular epithelial cells immunoreactive for NGAL and KIM-1, respectively, following CIS treatment. Scale bar is 50 μm . **D**, Bright field and fluorescence images of UMUC-3/GFP-Luc cells that were stably transduced with a lentivirus carrying both GFP and firefly luciferase genes. Scale bar is 80 μm . **E**, Orthotopic xenograft model. Representative image of bladders collected from female NSG mice (n=3) 1 week after implantation of UMUC-3/GFP-Luc cells (4×10^4 cells/animal). Black arrows indicate the tumors growing in the lamina propria. Scale bar is 500 μm . **F**, Representative merged bioluminescence/bright field images of the tumor-bearing NSG mice after weekly treatments with i.v. PBS (150 μL), i.v. DM1 (0.75 mg/kg, 150 μL), i.v. DM1-Bdd (0.75 mg/kg of drug content, 150 μL), i.t. MIT (1 mg/mL, 50 μL), i.t. DM1 (0.75 mg/kg, 50 μL), or i.t. DM1-Bdd (0.75 mg/kg, 50 μL) for 3 weeks (n=10/group). Images were acquired every week to monitor and compare tumor growth in each treatment group. **G**, Representative pictures of bladders excised from each animal group (additional recruitment of n=3/treatment group) 1 week after completing the treatment cycles. **H**, Kaplan-Meier cumulative survival plot of animals administered with different drugs (n=14/group). The significant differences in survival between the animals treated with i.v. DM1-Bdd and the other groups was evaluated using the Mantel-Cox log-rank test and the Benjamini & Hochberg adjusted p-values. **I-J**, Representative image(s) of bladder sections from the animals in each treatment group (n=3/group). The organs were harvested at the end of the 3-week treatment and then paraffin-embedded, sectioned, and stained with **(I)** H&E and **(J)** Ki67 (proliferation marker).




Fig 5: Therapeutic efficacy of DM1-Bdd in treating renal carcinoma.

A, Bright field and fluorescence images of Renca cells that were stably transduced with a lentivirus carrying both GFP and firefly luciferase genes. Scale bar is 80 μm . **B**, Syngeneic xenograft model. Representative image of the histological analysis of kidneys collected from female BALB/cJ mice ($n=3$) 1 week after implantation of murine Renca cells (4×10^3 cells/animal) in the renal capsules (black arrow). Scale bar is 1 mm. **C**, Representative merged bioluminescence/bright field images of BALB/cJ mice bearing Renca/GFP-Luc tumors after treatment with i.v. PBS (150 μL), i.v. DM1 (0.75 mg/kg, 150 μL), i.v. DM1-Bdd (0.75 mg/kg of drug content, 150 μL), or i.t. DM1 (0.75 mg/kg, 50 μL) weekly for 3 weeks ($n=10$ /group). **D**, Representative photos of the kidneys excised from the animals after completion of the treatment cycle (additional $n=4$ /group). Longitudinal comparisons of (**E**) bioluminescence signals at the region of interest (ROI = kidney), (**F**) body weight, and (**G**) survival among animals receiving different treatments ($n=14$ /group). The significant differences in survival

between animals treated with i.v. DM1-Bdd and the drugs was evaluated using the Mantel-Cox log-rank test and the Benjamini & Hochberg adjusted p-values. **H**, Representative kidney sections from animals of each treatment group (additional n=4/group). The sections were stained with H&E. The green, yellow, black, and blue arrows indicate the presence of pigment-laden macrophage, focal mineralization, interstitial fibrosis, and mononuclear cell infiltrates, respectively. Scale bars are 2 mm and 50 μ m.




Fig. 6: DM1-Bdd displays a safe toxicity profile.

A, Representative microscopic images of blood smears collected from female BALB/cJ mice after i.v. administration of PBS (150 μ L), DM1 (0.75 mg/kg, 150 μ L), DM1-Bdd (0.75 mg/kg of drug content, 150 μ L), or CIS (10 mg/kg, 150 μ L) as a positive control, weekly for 3 weeks. Black arrows indicate polychromatophilic macrocytes. Scale bar is 10 μ m.

B, Selected hematologic results obtained one week after completing the different treatment courses. (RBC = red blood cells and WBC = white blood cells). (Student's t-test; * p <0.05, ** p <0.01, and *** p <0.001).

C, Comparison of selected serum biochemical analytes, including liver enzyme activity (ALP, ALT and AST), muscle enzyme activity (AST and CK), and clearance of nitrogenous waste (BUN/CREA ratio). (ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; CK = creatine kinase; BUN = blood urea nitrogen; CREA = creatinine).

D, Histopathological analysis of the major organs (liver, spleen, heart, lungs, and kidneys) from animals administered with the different drug treatments. Black arrows indicate the increased of hepatocyte mitotic activity in liver. Blue arrows show the enhanced hepatic and splenic extramedullary hematopoiesis (EMH). The area in between the white arrows indicates depletions of erythrocytes and EMH

elements in the red pulp of the spleen. Red arrows highlight the presence of large and foamy macrophages in the alveoli. Yellow and green arrows indicate flattened renal tubular cells and necrotic sloughed debris of dying cells contained within the lumen, respectively. Scale bar is 30 μm .